Prior to the phosphodiesterase type-5 (PDE5) inhibitor era, ED treatment consisted of conservative options, including dialysis, correction of anemia using erythropoietin, testosterone supplementation, vacuum devices, penile or intraurethral vasoactive injections or surgical procedures, such as penile prosthesis and vascular surgery [26]. This evidence concerns the gene PDE5A and anemia (phenotype).